CytoSorbents Inc. (CTSO), 7 Deer Park Drive, Suite K, Monmouth Junction 08852. 732-329-8885. Phillip Chan, CEO. www.cytosorbents.com.
CytoSorbents, a Deer Park Drive-based biotech company and manufacturer of the CytoSorb blood purification device, has made a deal with Terumo Cardiovascular Systems, a subsidiary of Japanese company Terumo Corporation, to commercialize its device for cardiac surgery in multiple countries.
Under the terms of the agreement, Terumo has the exclusive rights to distribute the CytoSorb cardiopulmonary bypass procedure pack for intra-operative use during cardiac surgery in France, Sweden, Denmark, Norway, Finland, and Iceland.
“Our collaboration with CytoSorbents enables us to offer this innovative, easy-to-use blood purification therapy to address our customers’ most challenging cardiac cases,” said Arik Anderson, president of the perfusion and surgical devices division at Terumo. “CytoSorb integrates with the heart-lung machine platform, giving surgical teams for the first time the ability to safely reduce dangerous inflammatory mediators in real-time as they are being generated during cardiac surgery.”
“Terumo has an outstanding reputation for its commitment to the highest level of patient care, making it the ideal cardiac surgery partner to advance CytoSorb in these European countries,” said Phillip Chan, CEO of CytoSorbents.
CytoSorb is designed to filter out cytokines — chemicals that appear in the blood after trauma and can cause organ failure. The CytoSorb machine is intended to remove the inflammatory substances that appear in the blood during long heart surgeries. The company said the device has already been safely used in thousands of cardiac surgeries and that studies have shown it improves outcomes.
